| Revenue | DKK -10K | +11% |
| EBITDA | DKK -10K | -11% |
| Net profit | DKK 260K | +10984% |
| Total assets | DKK 1M | +37% |
| Equity | DKK 962K | +37% |
| Employees | — | — |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -2 | -23 | -14 | -7 | -7 | -7 | -7 | -8 | -9 | -10 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2 | -23 | -14 | -7 | -7 | -7 | -7 | -8 | -9 | -10 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2 | -23 | -14 | -7 | -7 | -7 | -7 | -8 | -9 | -10 |
| Net financials | -9 | -0 | -5 | -0 | -0 | 555 | 178 | 0 | 6 | 270 |
| Profit before tax | -11 | -23 | -20 | -8 | -8 | 548 | 170 | -8 | -2 | 260 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -11 | -23 | -20 | -8 | -8 | 548 | 170 | -8 | -2 | 260 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 39 | 36 | 16 | 16 | 1 | 556 | 733 | 734 | 740 | 1.010 |
| Equity | 39 | 28 | 9 | 1 | -7 | 541 | 711 | 704 | 701 | 962 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 8 | 8 | 15 | 8 | 15 | 22 | 30 | 39 | 49 |
| Total debt | 0 | 8 | 8 | 15 | 8 | 15 | 22 | 30 | 39 | 49 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CP Founder | Founder | 2015 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.7% | 66.7% | 2015 | |
Swan Neck Bio ApS | Company | 20.0% | 20.0% | 2023 |
| Person | Role here | Other companies |
|---|---|---|
| Claus Prahl Jørgensen | Founder | 0 companies |